Histology and Cytology Market

Global Histology and Cytology Market Size (2024 to 2032)

The size of the global histology and cytology market was worth USD 17.88 billion in 2023. The global market is anticipated to grow at a CAGR of 16.64% from 2024 to 2032 and be worth USD 71.45 billion by 2032 from USD 20.86 billion in 2024. 

MARKET DRIVERS

The growing prevalence of cancer and technical advancements are primarily driving the histology and cytology market forward. The growing prevalence of cancer, technological improvements in diagnostic and molecular techniques, and rising infection rate & healthcare-acquired infections (HAIs) are other significant factors driving the market growth. Cancer has become one of the leading causes of mortality globally, resulting in deaths that have accounted for the largest share of mortality. Cancer was the second leading cause of death globally, according to the World Health Organization (WHO) estimates, and is responsible for an estimated 9.8 million deaths in 2019. About 1 in 5 deaths is due to cancer globally.  70% of deaths from cancer occur in low- and middle-income countries. World Health Organization (WHO) estimates breast cancer is the most frequent cancer among women, impacting 2.3 million women globally and responsible for a higher number of cancer-related deaths. In 2019, it was estimated that about 629,000 women died from breast cancer, approximately 15% of all cancer deaths among women.

An increasing number of technological advancements in diagnostic and molecular techniques, increasing prevalence of the geriatric population, advancement of molecular genetics, rising prevalence of favorable reimbursement policies of the government, and growing research and development activities are further anticipated to accelerate the growth of the histology and cytology market. With advancements in digital pathology, data gathering techniques, and diagnostic care over the next few years, the global histology & cytology market is starting at a bright future. Additionally, the growing adoption of digital whole-slide-imaging (WSI) enables pathologists to visualize and capture the complete tissue on the slide, adoption of artificial intelligence (AI) and the adoption of digital technologies are the factors driving the market shortly.

MARKET RESTRAINTS

Lack of awareness among the public for diagnostic tests and diagnostic accuracy issues with histopathological and cytopathological tests are major restraining factors for the growth of the histology and cytology market. Furthermore, factors such as mislabelled specimens, stringent government rules, complicated procedures associated with histology and cytology, and low cytology tests restrict the expansion of the histology and cytology market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Histology and Cytology Market Analysis By Examination Type

• Histology
• Cytology

Based on the examination type, the cytology segment dominated the market in 2023. Incorporating Artificial Intelligence (AI) for developing advanced cytology systems is the key to segment growth. Cytology tests make both the diagnosis and screening of various cancer types. The companies primarily prefer cytology-based diagnostic methods for observations at the cellular level.

Global Histology and Cytology Market Analysis By Test Type

• Microscopy tests
  • Cytogenic tests
    • Karyotyping
    • Fluorescent In-situ Hybridization (FISH)
  • Polymerase Chain Reaction
• Molecular genetics tests
• Flow cytometry

Based on the test type, the cytogenic test segment accounted for a significant share of the histology and cytology market in 2023. Cytogenetics requires testing samples of tissue, blood, or bone marrow in a laboratory to look for chromosome changes, including broken, missing, or rearranged. Changing chromosomes is either a sign of a genetic disease or condition or some cancer. It provides a genome-wide snapshot of an individual's chromosomes by the process of pairing and arranging all of them in order and can reveal changes in chromosome numbers.

Global Histology and Cytology Market Analysis By End-User

• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes

Based on the end-user, the Hospital segment dominated the overall histology and cytology market in 2023 due to the increasing number of patients in hospitals, higher purchasing power, well-resourced surgery rooms, and improved health coverage for hospital-based healthcare services and highly skilled healthcare professionals.

REGIONAL ANALYSIS

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa

The North American region accounted for the largest share of the global histology and cytology market in 2023. The U.S. dominates the North American histology and cytology market. The region's growth is due to the high incidence of cancer, extensive R&D activities, the presence of market players, product approval, and established research infrastructure for pathology services. In North America, 606,520 Americans are expected to die of cancer in 2020, which translates to about 1,660 deaths per day. All these factors help to propel the histology and cytology market.

Asia-Pacific is expected to grow at the highest rate due to the increasing number of testing samples and raising awareness of the program's benefits. The regional market's growth is due to several factors such as increasing cancer awareness, researchers increasingly evaluating new cytology, and improving healthcare infrastructure. China and India are the dominating areas in this region. Nearly 65% of new cancer cases are diagnosed in developing nations, and by 2050, it could reach 75%. India accounted for more than 1.2 million cases in 2020, and every 1 in 10 individuals is at the risk of developing cancer. The region is also seeing significant improvement in healthcare facilities owing to increased spending by the government.

TOP COMPANIES IN THIS MARKET

Key players operating in the global histology and cytology market include Abbott, Hologic Inc., Becton, F. Hoffmann-La Roche Ltd, Sysmex Corporation, Dickinson and Company, Southwest Precision Instruments, LLC, Thermo Fisher Scientific Inc., Danaher, Life Technologies Corporation, Merck KGaA, Koninklijke Philips N.V., Perkin Elmer, and Trivitron Healthcare.

RECENT MARKET DEVELOPMENTS

• In 2021, Hologic announced the premarket approval (PMA) from USFDA for Company’s ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications.
• In 2021 Antech Diagnostics announced the availability of its new digital cytology scanner to veterinary practices across North America.
• In 2020, ELITechGroup’s Staining Technology Enhance with Aerospray Cytology Slide Stainer/Cytocentrifuge.